Rui Avelar - 16 Mar 2026 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
Chief Medical Officer and Head of Research & Development
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Issuer symbol
EOLS
Transactions as of
16 Mar 2026
Net transactions value
-$146,629
Form type
4
Filing time
18 Mar 2026, 20:00:32 UTC
Previous filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Avelar Rui Chief Medical Officer and Head of Research & Development 520 NEWPORT CENTER DR., SUITE 1200, NEWPORT BEACH /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar 18 Mar 2026 0001432063

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Options Exercise +8,804 +1.9% $0.000000* 460,538 16 Mar 2026 Direct F1
transaction EOLS Common Stock Sale $146,629 -29,996 -6.5% $4.89 430,542 17 Mar 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EOLS Performance Restricted Stock Units Options Exercise -8,804 -50% $0.000000* 8,802 16 Mar 2026 Common Stock 8,804 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 As previously reported, on February 7, 2024, the Reporting Person was granted 17,606 performance restricted stock units ("PSUs") at target pursuant to the Evolus, Inc. 2017 Omnibus Incentive Plan. The PSUs were subject to performance conditions based on certain pre-specified revenue and defined non-GAAP operating profit measured over the Issuer's 2024 and 2025 fiscal years. The Compensation Committee certified achievement at 100% of target, resulting in 17,606 earned PSUs. Of the earned PSUs, 50% vested and settled on March 16, 2026, resulting in the issuance of 8,804 shares of the Issuer's common stock. The remaining 8,802 PSUs remain outstanding and are scheduled to vest on February 7, 2027, subject to continued service. The number of shares reported reflects rounding adjustments applied in accordance with the terms of the award and administrative procedures.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of multiple PSU and restricted stock unit awards.
F3 The shares were sold in multiple trades at prices ranging from $4.8874 to $4.945. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Chief Medical Officer and Head of Research & Development